The European Patent Office (EPO) has published patent application EP4346870A1, detailing a bacteriocin for new applications. The publication date is March 11, 2026, and the applicant is Syngulon S.A. This application falls under IPC classifications related to antimicrobial agents and peptide compounds, suggesting a focus on novel therapeutic or industrial uses.

This is a patent publication, not a regulatory rule or enforcement action. It signifies the disclosure of an invention for which patent protection is sought. Companies in the pharmaceutical and biotechnology sectors should note this publication as it relates to intellectual property in the field of bacteriocins. No immediate compliance actions are required for regulated entities based solely on this patent publication.